Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to United Therapeutics Corporation (NASDAQ: UTHR) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret key disclosures. United Therapeutics is a biotechnology and pharmaceutical company whose common stock trades on the Nasdaq Global Select Market, as noted in its Form 8-K reports. The company develops therapies for pulmonary arterial hypertension and related lung diseases and pursues technologies to expand the availability of transplantable organs as part of its public benefit corporation mandate.
In these SEC filings, investors can review current reports on Form 8-K that describe material events such as quarterly earnings releases, clinical milestones, share repurchase arrangements, and shareholder meeting outcomes. For example, United Therapeutics has filed 8-Ks to furnish press releases on quarterly financial results, to report positive TETON-2 clinical data for nebulized Tyvaso in idiopathic pulmonary fibrosis, and to disclose accelerated share repurchase agreements under a board-authorized share repurchase program.
Filings also document corporate governance and compensation matters, including amendments and restatements of the company’s stock incentive plan, vote results from the annual meeting of shareholders, and the listing of common stock on the Nasdaq Global Select Market under the symbol UTHR. These documents provide insight into equity compensation structures, director elections, advisory votes on executive pay, and auditor ratification.
Through this page, you can quickly locate United Therapeutics’ 8-Ks and, where available, other forms such as 10-K annual reports, 10-Q quarterly reports, and Forms 3, 4, and 5 related to insider ownership and transactions. AI-powered summaries highlight the main points of lengthy filings, explain complex sections in simpler language, and draw attention to items that often matter to investors, such as revenue drivers, capital return actions, and significant clinical or regulatory updates. Real-time updates from EDGAR ensure that new UTHR filings appear promptly, helping users monitor the company’s regulatory and disclosure record in one place.
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised stock options and sold shares in a planned transaction. He exercised options for 8,300 shares of common stock at a price of $146.03 per share and received the underlying shares.
On the same date, he sold 8,300 shares of common stock in multiple open-market trades at weighted average prices ranging from about $471 to $479 per share under a pre-arranged Rule 10b5-1 plan entered on August 11, 2025. After these transactions, he directly owned 36,781 shares of UNITED THERAPEUTICS common stock.
Paul Mahon submitted a Form 144 proposing to sell 8,300 common shares via a stock options exercise with an intended transaction date of 02/19/2026. The filing also lists multiple recent dispositions by the same person, including sales of 8,300 shares on 02/05/2026 and 8,300 shares on 01/15/2026.
UNITED THERAPEUTICS Corp president and COO Michael Benkowitz reported option exercises and related sales of common stock held in family trusts. On February 17, 2026, trusts associated with him exercised options for 14,625 and 7,875 shares, then sold the resulting 22,500 shares in open-market transactions at $480.7536 per share under a pre-established Rule 10b5-1 trading plan entered into on June 3, 2025. After these indirect transactions, Benkowitz continued to hold 2,648 shares of common stock directly.
United Therapeutics director Malcolm Jan reported an open-market sale of company stock. On February 17, 2026, he sold 50 shares of United Therapeutics common stock at a price of $474.68 per share in a transaction coded as an open-market sale.
After this transaction, Jan directly holds 220 shares of United Therapeutics common stock. The sale was carried out under a pre-established Rule 10b5-1 trading plan that he entered into on September 11, 2025, which automates trades according to preset instructions.
An affiliate of UTHR has filed a notice under Rule 144 to sell 50 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of February 17, 2026 and an aggregate market value of 23734.00.
The 50 shares were acquired as restricted stock from the issuer on June 26, 2025, with payment recorded the same day. Over the past three months, the same seller has completed several additional 50‑share sales of UTHR common stock, each generating disclosed gross proceeds.
United Therapeutics Corporation’s president and COO, Michael Benkowitz, reported option exercises and related sales of United Therapeutics (UTHR) stock through trusts on February 9, 2026. Two trusts beneficially owned by him exercised stock options for 14,625 shares at $117.76 and 7,875 shares at $146.03, then sold the same numbers of shares at $474.6527 per share. The filing notes these transactions were executed under a Rule 10b5-1 trading plan entered into on June 3, 2025. After these indirect transactions, he also reports direct beneficial ownership of 2,648 common shares.
Wellington Management Group LLP and affiliated entities filed a Schedule 13G reporting beneficial ownership of 2,441,492 shares of United Therapeutics Corporation common stock as of December 31, 2025.
Their clients hold the shares of record, while Wellington entities have shared voting and dispositive power and certify the stake is held in the ordinary course, without a purpose of changing or influencing control.
United Therapeutics EVP and General Counsel Paul A. Mahon reported an option exercise and related share sales. On February 5, 2026, he exercised 8,300 stock options at an exercise price of $146.03 per share and sold the resulting shares in multiple trades under a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025.
Sale prices ranged from weighted averages of $480.9191 to $485.5179 across several transactions. Following these transactions, Mahon directly owned 36,781 shares of United Therapeutics common stock and 50,100 stock options.
Paul Mahon has filed a notice of proposed sale of 8,300 shares of United Therapeutics common stock, with an aggregate market value of 4,010,939.31. The shares are to be sold through Morgan Stanley Smith Barney LLC on or about 02/05/2026 on the NASDAQ.
The 8,300 shares to be sold were acquired on 02/05/2026 via a stock option exercise paid in cash. The filing also lists prior sales over the past three months, including four 11,000-share sales in November and December 2025 and two 8,300-share sales in January 2026, with gross proceeds ranging from 3,900,121.86 to 5,644,953.60. Shares outstanding are reported as 43,056,599.
United Therapeutics director Malcolm Jan reported a small planned share sale. On 02/03/2026, he sold 50 shares of United Therapeutics common stock at $474.23 per share in an open-market transaction coded "S." The sale was made under a pre-arranged Rule 10b5-1 trading plan that he entered into on September 11, 2025.
After this transaction, Jan beneficially owned 270 shares of United Therapeutics common stock, held in direct ownership form.